BMS-275291

Known as: D2163, N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide, BMS 275291 
A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2008
024620002008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
BACKGROUND BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the… (More)
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
2005
2005
PURPOSE To determine whether BMS-275291, a broad-spectrum matrix metalloproteinase inhibitor (MMPI), added to systemic… (More)
Is this relevant?
2004
2004
PURPOSE This pilot trial was performed to evaluate the safety, pharmacokinetics and feasibility of incorporating BMS-275291, a… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2004
2004
PURPOSE BMS-275291 is a novel broad-spectrum inhibitor of matrix metalloproteinase (MMPs) rationally designed to spare a class of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2004
2004
BACKGROUND This randomized, double-blind, placebo-controlled study was designed to assess whether the addition of the matrix… (More)
Is this relevant?
2003
2003
PURPOSE The purpose of this study was to evaluate the feasibility of incorporating a novel wound angiogenesis assay into a Phase… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 4
  • figure 3
Is this relevant?
2003
2003
Introduction The MMPs are a family of zinc-containing endopeptidases that degrade various components of the ECM. A number of MMPs… (More)
  • figure 1
  • figure 2
Is this relevant?
Review
2002
Review
2002
Bristol-Myers Squibb (BMS) is developing BMS-275291, which is a matrix metalloproteinase (MMP) inhibitor, for the potential… (More)
Is this relevant?
2001
2001
BMS-275291 is an p.o. bioavailable, sulfhydryl-based matrix metalloproteinase (MMP) inhibitor currently in clinical development… (More)
  • figure 1
  • table 1
  • table 3
  • figure 2
  • figure 3
Is this relevant?
2000
2000
  • P D Brown
  • Expert opinion on investigational drugs
  • 2000
Excessive or poorly regulated matrix metalloproteinase (MMP) activity has been implicated as a pathogenic factor in a range of… (More)
Is this relevant?